ArticleBMC cancer2024

Neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a phase II study protocol (SHAMROCK study).

Gavin P Dowling et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.